Does Empagliflozin Modulate Leukocyte-Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

• Main Authors: Francisco Canet (Author), Francesca Iannantuoni (Author), Aránzazu Martínez de Marañon (Author), Pedro Díaz-Pozo (Author), Sandra López-Domènech (Author), Teresa Vezza (Author), Blanca Navarro (Author), Eva Solá (Author), Rosa Falcón (Author), Celia Bañuls (Author), Carlos Morillas (Author), Milagros Rocha (Author), Víctor M. Víctor (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to cardiovascular risk reduction in patients with type 2 diabetes (T2D). However, their underlying molecular mechanisms remain unclear. This study aimed to evaluate the effects of empagliflozin, a novel potent and selective iSGLT-2...